The Embark Studios team may soon reveal ARC Raiders' development plans for 2026. For now, they have summarized the Cold Snap ...
Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback